We are live on ! Find out more
CYTO

Altamira Therapeutics Ltd
CYTO

Delisted

CYTO was delisted on the 19th of December, 2024.

Back to rankings

11 hedge funds and large institutions have $60.6M invested in Altamira Therapeutics Ltd in 2015 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

60% more capital invested

Capital invested by funds: $37.9M → $60.6M (+$22.8M)

57% more funds holding

Funds holding: 7 → 11 (+4)

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

Holders
11
Holders Change
+4
Holders Change %
+57.14%
% of All Funds
0.3%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
1
Reduced
2
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
WA
Wasatch Advisors
Utah
+$14.1M
2
TCM
Tekla Capital Management
Massachusetts
+$10.8M
3
OM
Opaleye Management
Massachusetts
+$1.66M
4
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$829K
5
TAM
Tocqueville Asset Management
New York
+$415K

Top Sellers

Rank Fund Capital Flow
1
CPCM
Clifton Park Capital Management
Delaware
-$415K
2
SFM
Sphera Funds Management
Israel
-$415K
3
SIM
Spark Investment Management
New York
-$85K
4
TRCT
Tower Research Capital (TRC)
New York
-$14K
Name Holding Trade Value Shares
Change 		Change in
Stake
WA
1
Wasatch Advisors
Utah
$13.4M +$14.1M +34 New
BAMS
2
Bellevue Asset Management (Switzerland)
Switzerland
$10.7M – – –
TCM
3
Tekla Capital Management
Massachusetts
$10.4M +$10.8M +26 New
Fidelity Investments
4
Fidelity Investments
Massachusetts
$8.23M – – –
CPCM
5
Clifton Park Capital Management
Delaware
$7.73M -$415K -1 -5%
RCM
6
RA Capital Management
Massachusetts
$4.57M – – –
OM
7
Opaleye Management
Massachusetts
$1.73M +$1.66M +4 New
Alyeska Investment Group
8
Alyeska Investment Group
Illinois
$1.29M +$829K +2 +200%
SAM
9
Sectoral Asset Management
Quebec, Canada
$1.11M – – –
TAM
10
Tocqueville Asset Management
New York
$486K +$415K +1 New
SFM
11
Sphera Funds Management
Israel
$316K -$415K -1 -50%
OA
12
Omega Advisors
New York
$174K – – –
KeyBank National Association
13
KeyBank National Association
Ohio
$150K – – –
HCM
14
Harvey Capital Management
Florida
$116K – – –
Goldman Sachs
15
Goldman Sachs
New York
$93K – – –
Royal Bank of Canada
16
Royal Bank of Canada
Ontario, Canada
$58K – – –
UBS Group
17
UBS Group
Switzerland
$31K – – –
Bank of America
18
Bank of America
North Carolina
$4K – – –
Morgan Stanley
19
Morgan Stanley
New York
$2K – – –
RFC
20
Russell Frank Company
Washington
$2K – – –
SIM
21
Spark Investment Management
New York
– -$85K – –
TRCT
22
Tower Research Capital (TRC)
New York
– -$14K – –

CYTO Hedge Fund Activity: Q2 2015 in Review

11 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in Altamira Therapeutics Ltd (CYTO) for Q2 2015, worth a combined $60.6M — up 60% from $37.9M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new CYTO positions and 0 closed out — a net gain of 4 holders — while 1 added to existing stakes and 2 trimmed.

The largest buyer was Wasatch Advisors, opening a new position worth an estimated $14.1M. The largest seller was Clifton Park Capital Management, cutting an estimated $415K.

  • 11 institutional investors held Altamira Therapeutics Ltd (CYTO) as of Q2 2015, up from 7 in Q1 2015.
  • Funds reported $60.6M of Altamira Therapeutics Ltd stock for Q2 2015, up 60% quarter-over-quarter.
  • 4 funds opened new Altamira Therapeutics Ltd positions in Q2 2015 and 0 closed out, a net change of +4 holders.
  • The largest Altamira Therapeutics Ltd buyer in Q2 2015 was Wasatch Advisors, an estimated $14.1M added.
  • The largest Altamira Therapeutics Ltd seller in Q2 2015 was Clifton Park Capital Management, an estimated $415K sold.

Based on aggregated 13F filings for Q2 2015.